[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.145.176.252. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Editor's Correspondence
October 23, 2000

β-Blockers in Congestive Heart Failure: Is There a Difference Between Classes?

Arch Intern Med. 2000;160(19):3005-3006. doi:

I read with great interest the article by Bonet et al1 regarding the benefits of vasodilating and nonvasodilating agents. Clearly, it would be useful clinically to know if vasodilating β-blockers such as carvedilol are more effective than less expensive, nonvasodilating β-blockers such as metoprolol.

The authors draw the conclusion that vasodilating β-blockers had a greater effect on overall mortality than nonvasodilating β-blockers. That conclusion is a matter of statistical interpretation and not wholly supported by the authors.

First Page Preview View Large
First page PDF preview
First page PDF preview
×